The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Analysis on the current status of targeted drug delivery to tumors
Open accessAbstract
Targeted drug delivery to tumor sites is one of the ultimate goals in drug delivery. Recent progress in nanoparticle engineering has certainly improved drug targeting, but the results are not as good as expected. This is largely due to the fact that nanoparticles, regardless of how advanced they are, find the target as a result of blood circulation, like the conventional drug delivery systems do. Currently, the nanoparticle-based drug delivery to the target tumor tissues is based on wrong assumptions that most of the nanoparticles, either PEGylated or not, reach the target by the enhanced permeation and retention (EPR) effect. Studies have shown that so-called targeting moieties, i.e., antibodies or ligands, on the nanoparticle surface do not really improve delivery to target tumors. Targeted drug delivery to tumor sites is associated with highly complex biological, mechanical, chemical and transport phenomena, of which characteristics vary spatiotemporally. Yet, most of the efforts have been focused on design and surface manipulation of the drug carrying nanoparticles with relatively little attention to other aspects. This article examines the current misunderstandings and the main difficulties in targeted drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Targeted drug delivery to tumors: Myths, reality and possibility
Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935
Self-citationHuman serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration
De Jong, W. H., Hagens, W. I., Krystek, P., Burger, M. C., Sips, A. J. A. M., & Geertsma, R. E. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.12.037 · Cited by 1,615
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Cited by
Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Controlled drug delivery systems: Past forward and future back
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.054 · Cited by 720
Self-citationRecent applications of PLGA based nanostructures in drug delivery
Mir, M., Ahmed, N., & Rehman, A. U. (2017) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2017.07.038 · Cited by 621
Molecularly Imprinted Polymers: Antibody Mimics for Bioimaging and Therapy
Haupt, K., Medina Rangel, P. X., & Bui, B. T. S. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00428 · Cited by 561
Facing the Truth about Nanotechnology in Drug Delivery
Park, K. (2013) · ACS Nano · doi:10.1021/nn404501g · Cited by 544
Self-citationWu, X., Sun, X., Guo, Z., Tang, J., Shen, Y., James, T. D., Tian, H., & Zhu, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja412380j · Cited by 539
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids
Wang, Q., Zhuang, X., Mu, J., Deng, Z.-B., Jiang, H., Zhang, L., Xiang, X., Wang, B., Yan, J., Miller, D., et al. (2013) · Nature Communications · doi:10.1038/ncomms2886 · Cited by 525
Polymeric Nanostructures for Imaging and Therapy
Elsabahy, M., Heo, G. S., Lim, S.-M., Sun, G., & Wooley, K. L. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00135 · Cited by 508
Yang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471
PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems
Ghaffarizadeh, A., Heiland, R., Friedman, S. H., Mumenthaler, S. M., & Macklin, P. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005991 · Cited by 451
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Tewabe, A., Abate, A., Tamrie, M., Seyfu, A., & Abdela Siraj, E. (2021) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s313968 · Cited by 375
Han, S.-S., Li, Z.-Y., Zhu, J.-Y., Han, K., Zeng, Z.-Y., Hong, W., Li, W.-X., Jia, H.-Z., Liu, Y., Zhuo, R.-X., et al. (2015) · Small · doi:10.1002/smll.201402865 · Cited by 269
Magnetic fluid hyperthermia: Advances, challenges, and opportunity
Kozissnik, B., Bohorquez, A. C., Dobson, J., & Rinaldi, C. (2013) · International Journal of Hyperthermia · doi:10.3109/02656736.2013.837200 · Cited by 267
Schleich, N., Po, C., Jacobs, D., Ucakar, B., Gallez, B., Danhier, F., & Préat, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.059 · Cited by 238
Shi, Y., Lammers, T., Storm, G., & Hennink, W. E. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201600160 · Cited by 174
Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip
Kwak, B., Ozcelikkale, A., Shin, C. S., Park, K., & Han, B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.08.027 · Cited by 165
Self-citationAbd Ellah, N. H., & Abouelmagd, S. A. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1213238 · Cited by 164
Seabra, A. B., Justo, G. Z., & Haddad, P. S. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.01.005 · Cited by 151
Iron oxide-loaded nanotheranostics: major obstacles to in vivo studies and clinical translation
Schleich, N., Danhier, F., & Préat, V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.024 · Cited by 124
Han, B., Qu, C., Park, K., Konieczny, S. F., & Korc, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.003 · Cited by 53
Self-citationLiu, Y., Fens, M. H. A. M., Capomaccio, R. B., Mehn, D., Scrivano, L., Kok, R. J., Oliveira, S., Hennink, W. E., & van Nostrum, C. F. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.040 · Cited by 25
A review on Stimuli-pH responsive liposomal formulation in cancer therapy
Jayapriya, P., Pardhi, E., Vasave, R., Guru, S. K., Madan, J., & Mehra, N. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105172 · Cited by 24
Metadata
- Authors
- Kwon, I. K., Lee, S. C., Han, B., & Park, K.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 164
- Issue
- 2
- Pages
- 108-114
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2066459637
- Cited by
- 404
- References
- 54
- FWCI
- 16.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.